Search

Your search keyword '"Marshall, Glenn M."' showing total 893 results

Search Constraints

Start Over You searched for: Author "Marshall, Glenn M." Remove constraint Author: "Marshall, Glenn M."
893 results on '"Marshall, Glenn M."'

Search Results

1. Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis

2. The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis

3. Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML

4. A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer

6. Precision-guided treatment in high-risk pediatric cancers

7. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

8. Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia

10. Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma

12. School Students with Chronic Illness Have Unmet Academic, Social, and Emotional School Needs

13. Facilitating Engagement with School in Students with Chronic Illness through Positive Education: A Mixed-Methods Comparison Study

14. A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma

18. Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia

19. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

23. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance

24. The prenatal origins of cancer

25. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma

26. Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives

30. Supplementary Tables S1-S7 from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

31. Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

32. Supplementary Figures and Figure Legends from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

33. Supplementary Materials and Methods from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

34. Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

35. High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

36. Parents’ expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial

37. Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine Trial

40. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma

45. Supplementary Table S1 from Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN

46. Supplementary Table S1 from Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

47. Data from Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant

48. Supplementary Figure S1 from Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

49. Figure S1-S6 from Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN

50. Supplementary Figure S4 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

Catalog

Books, media, physical & digital resources